Endo Health price target lowered to $36 from $42 at Stifel Stifel reduced its price target on Endo Health after the FDA denied the company's Citizen Petition on OpanaER. The firm was surprised by the FDA's decision ,and thinks the company will now have to restructure, but keeps a Buy rating based on valuation.
News For ENDP From The Last 14 Days
Check below for free stories on ENDP the last two weeks.
Endo Health subsidiary receives CE Mark of RetroArc system American Medical Systems, an Endo Health Solutions subsidiary, announced CE Mark of its RetroArc Retropubic Sling System for treatment of female stress urinary incontinence. The system maintains familiar features of transvaginal retropubic sling systems while incorporating new enhancements and the ability to make fine-tuned adjustments to better meet the needs of physicians, the company said.